Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The endometriosis market was valued at USD 727.58 Million in 2025. It is poised to grow at a CAGR of 5.21% during the forecast period of 2026-2035, and reach USD 1209.07 Million by 2035. The rising prevalence of endometriosis, increasing awareness, and delayed diagnosis are driving demand. Advancements in hormonal therapies, improved diagnostic methods, and growing investments in women’s health further support market growth.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Endometriosis Market

United States: The Endometriosis Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. 31 force majeure declarations by polymer suppliers, polypropylene and polyethylene price spikes, and chemical manufacturer surcharges of up to 30% are flowing through supply chains. U.S. consumer inflation is projected at 4.2% for 2026, above pre-war forecasts, with fuel costs above USD 4 per gallon compressing household discretionary budgets. Retail supply chains are absorbing the combined impact of 30% higher freight costs, 15-20% packaging material inflation, and rising transport fuel costs, compressing retailer margins. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets.

Iran: Iran's domestic Endometriosis sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.

Israel: Israel's Endometriosis sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalise.

Key Takeaways

Government

  • Relevant consumer protection agencies should monitor retail pricing for evidence of disproportionate margin-taking on top of genuine supply cost increases, ensuring that conflict-related cost inflation is not being amplified by opportunistic pricing behaviour.
  • Governments should consider targeted consumer support measures for lower-income households most exposed to rising fuel and food costs, preventing conflict-driven inflation from creating acute hardship among economically vulnerable populations.
  • Trade authorities should work with the endometriosis industry to identify import diversification opportunities that reduce dependence on Gulf-disrupted supply chains, stabilising product availability and moderating consumer price inflation.

Market

  • U.S. consumer inflation projected at 4.2% for 2026, gasoline above USD 4 per gallon, and global food price increases from fertilizer and logistics inflation are creating the most challenging consumer spending environment since 2022.
  • Premium and essential categories within the endometriosis market show different demand trajectories: premium segments serving ultra-high-net-worth consumers remain resilient, while mass-market discretionary segments face meaningful softening.
  • Supply chain cost increases from 30% higher freight, 15-20% packaging inflation, and rising input material costs are compressing retailer and brand margins, creating pressure for pricing adjustments that may further moderate volume demand.

Procurement

  • Consumer goods procurement teams should review packaging material sourcing, building 60-90 day buffer inventory of petroleum-derived packaging materials before further feedstock cost increases from the Gulf supply shock are transmitted into manufacturing costs.
  • Logistics procurement managers should lock in freight contracts at current rates before further diesel cost increases are passed through by carriers, and evaluate route optimisation strategies that reduce fuel cost exposure.
  • Retail and brand buyers should update 2026 cost models to incorporate 30% higher freight costs, 15-20% packaging material inflation, and rising input material prices, ensuring that margin targets and pricing strategies reflect the new cost environment.

Key Market Trends and Insights

  • The oral segment dominated the overall market, accounting for more than 49% revenue share in the historical period.
  • The hormone therapy segment held the highest market share, exceeding 79% in the historical period.
  • Based on region, the United States held a dominant share of approximately 37% in the historical period, driven by strong healthcare infrastructure and high diagnosis rates.

Market Size and Forecast

  • Market Size (2025): USD 727.58 Million
  • Projected Market Size (2035): USD 1209.07 Million
  • CAGR (2026-2035): 5.21%
  • In March 2026, research highlights precision medicine approaches for endometriosis, targeting individual disease biology to develop personalized therapies, potentially improving symptom management and patient outcomes.

  • In March 2026, EndoCyclic Therapeutics announced FDA clearance of its Investigational New Drug (IND) application for ENDO‑205, a first‑in‑class non‑hormonal precision peptide therapeutic for endometriosis. This suggests an important step toward clinical trials of a novel treatment modality beyond hormone suppression.

  • In December 2025, Hope Medicine’s HMI-115 received FDA Fast Track designation for treating moderate-to-severe endometriosis pain. The monoclonal antibody showed strong Phase II results, significantly reducing pain while maintaining hormonal balance, highlighting a promising non-hormonal treatment pipeline.

Endometriosis Market Overview

Endometriosis is a chronic gynecological condition characterized by the growth of endometrial-like tissue outside the uterus, causing pain and infertility. The market is driven by rising disease prevalence, increasing awareness, and improved diagnostic techniques. Advancements in hormonal therapies and minimally invasive surgeries are enhancing treatment outcomes. Growing research investments and focus on women’s health are further supporting market expansion. The market reached a value of approximately USD 727.58 Million in 2025.

Endometriosis Market Growth Drivers

Rising FDA Clearance Driving the Endometriosis Market Expansion

The shift toward non-hormonal treatments is a key market driver. For instance, in January 2026, EndoCyclic Therapeutics received FDA clearance for its IND application for ENDO‑205, a first-in-class peptide therapy targeting endometriotic lesions. This innovation is expected to reduce reliance on invasive procedures, alleviate pelvic pain, and expand patient access, supporting sustainable growth in the treatment market.

Endometriosis Market Trends

Key trends shaping the market include personalized therapies, non-hormonal treatments, precision medicine, improved symptom management, reduced laparoscopic surgery, and enhanced patient outcomes.

Increasing Precision Medicine Approaches Shaping the Market Landscape

The growing focus on personalized therapies is driving endometriosis market trends. For instance, in March 2026, researchers at Yale School of Medicine (YSM) highlighted precision medicine approaches targeting individual patient biology. This strategy could reduce reliance on traditional hormonal therapy and invasive interventions like laparoscopic surgery, improve outcomes for patients with pelvic pain, and signal strong future growth in endometriosis treatment.

Endometriosis Market Segmentation

Market Breakup by Type

  • Deeply Infiltrating Endometriosis
  • Superficial Peritoneal Endometriosis
  • Endometriomas
  • Others

Market Breakup by Drug Class

  • NSAIDs
  • Oral Contraceptive
  • Gonadotropin Releasing Hormone
  • Others

Market Breakup by Route of Administration

  • Oral
  • Injectable
  • Others

Market Breakup by Treatment Type

  • Pain Medication
  • Hormone Therapy

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by End User

Market Breakup by Region

  • United States
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Japan
  • India

Endometriosis Market Share

Hormone Therapy Expected to Lead the Market Segment by Treatment Type

The hormone therapy segment accounted for the largest share, exceeding 79% during the historical period, supported by its effectiveness in managing symptoms and slowing disease progression. Increasing clinical preference for targeted treatments and long-term management approaches continues to drive adoption. The use of hormonal therapy remains central to treatment strategies, ensuring sustained market dominance and improved patient outcomes.

Endometriosis Market Analysis by Region

The United States held a dominant share of approximately 37% during the historical period, driven by advanced healthcare infrastructure and higher diagnosis rates. Strong awareness initiatives and access to specialized care contribute to early intervention and treatment uptake. Increasing focus on managing pelvic pain associated with endometriosis further supports market growth, alongside continuous innovation in therapeutic solutions and patient care delivery.

Leading Players in the Endometriosis Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Bayer AG

Bayer AG, headquartered in Leverkusen, Germany, was established in 1863. The company has a strong presence in women’s health, offering therapies for gynecological conditions. Its portfolio includes dienogest-based treatments widely used for endometriosis management, addressing symptoms such as pain and lesion progression through targeted hormonal approaches and long-term disease control strategies.

Pfizer Inc.

Pfizer Inc., headquartered in New York, United States, was founded in 1849. The company focuses on innovative therapeutics across multiple disease areas, including women’s health. Its portfolio includes treatments supporting anti-inflammatory treatment approaches and pain management solutions, contributing to improved symptom relief and quality of life in patients with endometriosis and related conditions.

AbbVie Inc.

AbbVie Inc., headquartered in North Chicago, United States, was established in 2013. The company is a key player in endometriosis treatment, particularly through its focus on advanced hormonal therapies. Its portfolio includes elagolix, an oral GnRH antagonist designed to manage moderate to severe pain, offering a non-surgical option for effective symptom control.

AstraZeneca

AstraZeneca, headquartered in Cambridge, United Kingdom, was founded in 1999. The company emphasizes innovation in reproductive and chronic disease management. While not a primary endometriosis-focused player, its broader portfolio supports treatments addressing pelvic pain and inflammatory pathways, contributing to improved therapeutic outcomes in women’s health and related disorders.

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market are ObsEva, Teva Pharmaceuticals, Astellas Pharma Inc., and Eli Lilly and Company.

Key Questions Answered in the Endometriosis Market Report

  • What was the endometriosis market value in 2025?
  • What is the endometriosis market forecast outlook for 2026-2035?
  • What major factors aid the demand for endometriosis market?
  • How has the market performed so far, and how is it anticipated to perform in the coming years?
  • What are the market’s major drivers, opportunities, and restraints?
  • What are the major endometriosis market trends?
  • Which type is expected to dominate the market segment?
  • Which drug class is expected to dominate the market segment?
  • Which route of administration is expected to dominate the market segment?
  • Which treatment type is expected to dominate the market segment?
  • Which distribution channel is expected to dominate the market segment?
  • Who are the key players in the endometriosis market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2025
Historical Period 2019-2025
Forecast Period 2026-2035
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Drug Class
  • Route of Administration
  • Treatment Type
  • Distribution Channel
  • End User
  • Region
Breakup by Type
  • Deeply Infiltrating Endometriosis
  • Superficial Peritoneal Endometriosis
  • Endometriomas
  • Others
Breakup by Drug Class
  • NSAIDs
  • Oral Contraceptive
  • Gonadotropin Releasing Hormone
  • Others
Breakup by Route of Administration
  • Oral
  • Injectable
  • Others
Breakup by Treatment Type
  • Pain Medication
  • Hormone Therapy
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Others
Breakup by Region
  • United States
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Bayer AG
  • Pfizer Inc.
  • Abbvie Inc.
  • Astrazeneca
  • ObsEva
  • Teva Pharmaceuticals
  • Eli Lilly and Company
  • Astellas Pharma Inc.

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us